ERBB2 and breast carcinoma: The possible reasons are that HR-positive patients are not sensitive to chemotherapy, or HR-negative breast cancer is characterized by high expression of proliferative cluster genes [49], or HER2-positive and HR-negative tumors are highly dependent on the HER2 gene and therefore show a good response to anti-HER2-targeted therapy.